Arterial hypertension and cognitive disorders. Mexidol's effectiveness

Time codes:
  • 02:30

    Portrait of a patient with arterial hypertension

  • 05:24

    The brain is an organ of the target of arterial hypertension. 

  • 06:00

    Approach to early diagnosis of patients 

  • 08:00

    Montreal scale for evaluating cognitive functions (Mosa –Test)

  • 09:08

    Digital symbol replacement test 

  • 09:40

    Trail Making Test (TMT)

  • 11:10

    Target levels of blood pressure 

  • 12:15

    Antihypertensive drugs and related risk factors

  • 14:10

    Features of neuroprotectors for patients with arterial hypertension

  • 19:14

    Mexidol® is an effective neuroprotector with evidence

  • 19:50

    Long -term and consistent therapy with Mexidol® in a memo study  

Ekusheva Evgenia Viktorovna - MD, professor, head. Department of Nervous Diseases and Neurorebition of the Academy of Postgraduate Education of the Federal State Budgetary Educational Institution of the FGBC FMBA of Russia

Kochetkov Alexey Ivanovich - Ph.D., associate professor of the Department of Therapy and Polymorbid Pathology named after Acad. M.S. VLUSSi FSBEI DPO RMANPO of the Ministry of Health of Russia

Announcement:

The brain is one of the main target organs of arterial hypertension. The most common cerebral symptoms of arterial hypertension should include headaches mainly in the nape area, as a rule, in the morning, dizziness of varying degrees of severity, noise in the ears and visual impairment. Mexidol® is a drug that has an evidence base and is effective for patients with arterial hypertension.

Time codes:
  • 02:30

    Portrait of a patient with arterial hypertension

  • 05:24

    The brain is an organ of the target of arterial hypertension. 

  • 06:00

    Approach to early diagnosis of patients 

  • 08:00

    Montreal scale for evaluating cognitive functions (Mosa –Test)

  • 09:08

    Digital symbol replacement test 

  • 09:40

    Trail Making Test (TMT)

  • 11:10

    Target levels of blood pressure 

  • 12:15

    Antihypertensive drugs and related risk factors

  • 14:10

    Features of neuroprotectors for patients with arterial hypertension

  • 19:14

    Mexidol® is an effective neuroprotector with evidence

  • 19:50

    Long -term and consistent therapy with Mexidol® in a memo study  

Block of articles on this topic

Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"

Presidium of the Council of Experts:

Martynov A.I., MD, professor, academician of the Russian Academy of Sciences, professor of the Department of Hospital therapy No. 1 of the Federal State Budgetary Institution “Moscow State Medical and Dental University named after A.I. Evdokimova "of the Ministry of Health of Russia, President of the Russian Scientific Medical Society of therapists (RNDMO), Moscow

Tanashian M.M., MD, professor, corresponding member of the Russian Academy of Sciences, deputy. Director for scientific work of the FGBN “Scientific Center of Neurology”, Moscow

Malyavin A.G., MD, professor at the Department of Testions and Pulmonology Faculty of Faculty of Faculty of FSBEI in the Moscow State Medical and Dental University named after A.I. Evdokimova ”of the Ministry of Health of Russia, chief freelance pulmonologist of the Ministry of Health of Russia for the Central Federal District, General Secretary of the RND, Moscow

Participants in the Council of Experts:

Bogolepova A.N. D.M.N., head of the cognitive violations department of the Federal Center for Brain and Neurotechnology, FMBA of Russia, professor of the Department of Neurology, Neurosurgery and Medical Genetics of Faculty of Faculty of Faculty of Medicine in the Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of Russia, Moscow

Borovkova N.Yu., MD, the first deputy. Director of the Institute of Therapy, Professor of the Department of Hospital Therapy and General Medical Practice of the Volga Research Medical University of the Ministry of Health of Russia, Nizhny Novgorod.

Eliseeva L.N., MD, professor, head. Department of Faculty of Faculty of FSBENSI and Kuban State Medical University of the Ministry of Health of Russia, Chairman of the Krasnodar Regional Branch of the RND, Krasnodar

Zhuravleva M.V., MD, professor, professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases of the FGAOU in the First Moscow State Medical University named after THEM. Sechenova "of the Ministry of Health of Russia (Sechenov University), the main freelance specialist - a clinical pharmacologist of the Department of Health of the city of Moscow, Moscow

Zakharov V.V., MD, professor at the Department of Nervous Diseases and Neurosurgery of the FGAOU in "First Moscow State Medical University named after THEM. Sechenova "of the Ministry of Health of Russia (Sechenov University), Moscow

Koryagina N.A., MD, professor at the Department of Clinical therapy of FSBEI in Perm State Medical University named after Academician E.A. Wagner ”of the Ministry of Health of Russia, Vice-President of the Association of Doctors of the therapeutic Profile of the Perm Territory, Chairman of the Perm Regional Department of the RND, Chief Forest Transportist of the Ministry of Health of the Perm Territory, Perm Perm

Mikhin V.P., MD, professor, head. Department of Internal Diseases No. 2 of the FSBEI in “Kursk State Medical University” of the Ministry of Health of Russia, Kursk

Osipova I.V., MD, professor, head. Department of Faculty Therapy and Professional Diseases of the FSBEI in Altai State Medical University of the Ministry of Health of Russia, Barnaul

Ostroumova O.D., MD, professor, head. Department of Therapy and Polymorbid Pathology of the Federal State Budgetary Institution of the DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow

Poznyak A.O., MD, professor, head. The Department of Therapy, Geriatrics and the General Practice of the Kazan State Medical Academy - a branch of the Federal State Budgetary Institution of the DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Kazan Kazan

Portnyagina U.S., Ph.D., Associate Professor of the Department of Internal Diseases and General Personnel Practice (Family Medicine) of the FGOU FGAOU in North-East Federal University named after M.K. Ammosova ”, the main freelance specialist in therapy and general medical practice of the Ministry of Health of the Republic of Sakha (Yakutia), Yakutsk

Statsenko M.E., MD, professor, head. Department of Internal Diseases of the FSBEI in Volgograd State Medical University of the Ministry of Health of Russia, Volgograd

Tyrenko V.V., MD, professor, head of the department and clinic of the faculty therapy of the Federal State Budgetary Institution “Military Medical Academy named after S.M. Kirov »of the Ministry of Defense of the Russian Federation, chief cardiologist of the Ministry of Defense of the Russian Federation, St. Petersburg St.

Chesnikova A.I., MD, professor, head. Department of Internal Diseases No. 1 of the Federal State Budgetary Institution “Rostov State Medical University” of the Ministry of Health of Russia, the main freelance specialist in therapy of the Southern Federal District, Rostov-on-Don

Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension

Authors:
O.D. Ostroumova, A.I. Kochetkov, N.A. Shatalova

Personal: Mexidol® and Mexidol® Fort 250 as part of the sequential therapy for cognitive disorders in comorbide patients with joint pathology against the background of arterial hypertension and coronary heart disease

Authors:
L.N. Eliseeva, S.V. Kartashova

FSBEI in Kuban State Medical University of the Ministry of Health of Russia, Krasnodar

The importance of identifying and diagnosing signs of brain damage to arterial hypertension

Authors:
T.M. Ostroumova, O.D. Ostroumova

International multicenteric randomized double-tied placebo-controlled study of evaluating the effectiveness and safety of sequential therapy of patients with chronic brain ischemia drugs Mexidol® and Mexidol® Forte 250 (study of memo): Subanalysis results in patients with arterial hypertension

V.V. Zakharov 1 , O.D. Ostroumova 1.2 , A.I. Kochetkov 2 , M.V. Klepikov 2 , A.I. Fedin 3

1 FGAOU VO "First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University);
2 FSBEI of DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow;
3 FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow

Place of publication:
therapy No. 1 (63) 2023

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com